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Abstract
Background. The aim of this study was to evaluate the
effect of pioglitazone treatment on the progression of
subclinical atherosclerosis and insulin resistance in re-
nal allograft recipients with no preoperative history of
diabetes.
Methods. Eighty-three patients without diabetes were
randomly assigned to either the pioglitazone group or
the control group. Carotid intima–media thickness
(IMT), serum adiponectin level and lipid profile were
assessed before transplantation and at 12 months after
transplantation. Insulin secretory function and insulin re-
sistance were evaluated by the oral glucose tolerance
test.
Results. The pioglitazone group showed a significant re-
duction in the mean and maximum carotid IMT com-
pared with the control group after 12 months (mean
carotid IMT, 0.05 ± 0.04 vs −0.03 ± 0.07mm, P <
0.001; maximum carotid IMT, 0.08 ± 0.05 vs −0.05 ±
0.09mm, P < 0.001). Pioglitazone increased the adipo-
nectin level, and the change in adiponectin was negative-
ly correlated with carotid IMT changes. Pioglitazone
treatment increased the insulin sensitivity index compared
with the control group (−0.8 ± 3.1×10−2 vs +1.1 ±
3.7×10−2, P = 0.036).
Conclusions. These results suggest that pioglitazone treat-
ment reduces the progression of carotid IMT and improves
insulin resistance in renal allograft recipients without a his-
tory of diabetes.
Trial Registration. Clinicaltrials.gov Identifier:
NCT00598013
Keywords: carotid intima–media thickness; insulin resistance;
pioglitazone; renal allograft
Introduction
Cardiovascular disease (CVD) is a common cause of mor-
bidity and mortality after kidney transplantation [1]. The
annual risk of CVD is 3.5–5% in renal transplant recipi-
ents, 50-fold higher than in the general population [2,3].
The measurement of carotid intima–media thickness
(IMT) by high-resolution B-mode ultrasonography is an
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easy, reliable and non-invasive method for assessing car-
diovascular risk in renal transplant recipients [4–6].
Thiazolidinediones act as insulin sensitizers, leading to
improved glycaemic control with reduced insulin require-
ments in patients with diabetes mellitus. Pioglitazone and
rosiglitazone are effective and safe oral agents for post-
transplant diabetes mellitus (PTDM), and rosiglitazone im-
proves endothelial function in renal transplant recipients
with glucose intolerance [7,8]. Furthermore, pioglitazone
has been shown to decrease carotid IMT and improve car-
diovascular risk markers, including adiponectin, indepen-
dently of glycemic control in patients with type 2 diabetes
mellitus [9–11]. Recently, hypoadinponectinaemia was
shown to be associated with insulin resistance, glucose in-
tolerance and arteriosclerotic risk factors after renal trans-
plantation [12,13].
In light of these data, we investigated the effect of pio-
glitazone treatment on the progression of carotid IMT and
insulin resistance in renal transplant recipients without a
history of diabetes.
Materials and methods
Study subjects and study design
This was a prospective, randomized open-label study. Patients on dialysis
who received a kidney transplant were eligible to participate in the study
if they were ≥18years old, had no previous history of organ transplanta-
tion and were not currently using steroids or other immunosuppressants.
Patients were excluded if they had diabetes before transplantation with a
fasting glucose ≥7.0mmol/l or 2-h post-load glucose ≥11.1mmol/l,
symptomatic CVD (coronary artery disease, cerebrovascular disease or
peripheral vascular disease), uncontrolled hypertension, severe metabolic
or infectious disease, hepatic disease, congestive heart failure, kidney
transplantation from a cadaver donor or an unstable condition of the trans-
planted kidney (serum creatinine ≥2.0mg/dl and/or blood urea nitrogen
≥30mg/dl). Patients who were taking a stable dose of statins 2 months
prior were allowed to participate in the study. During the study, they main-
tained their dosage of statin. Statin use was not allowed after patients had
entered into the study. The study protocol was approved by the ethics
committee of the Yonsei University College of Medicine. All subjects
gave informed consent. Participation in this study was proposed to all el-
igible patients who satisfied the inclusion/exclusion criteria, and no selec-
tions were made prior to patient consent. A total of 83 renal allograft
recipients who underwent kidney transplantation from November 2004
to September 2006 were enrolled in this study. They were randomly as-
signed to either the pioglitazone treatment group or the control group ac-
cording to a computer-generated allocation schedule. The pioglitazone
treatment group received 30mg pioglitazone starting at 2weeks after renal
transplantation for 12 months. All patients were provided counseling re-
garding diet and exercise. Patients were advised to eat a stable-calorie diet
and instructed to maintain the same level of physical activity throughout
the study. Patients visited our clinic two times per week for the first month
after transplantation, every week for the second and third month, every 2
weeks for the fourth month and monthly thereafter. Vital signs and phys-
ical examination, compliance with the study drug and adverse events were
assessed at each visit. We measured carotid IMT before and 12 months
after renal transplantation. Oral glucose tolerance tests (OGTTs) were per-
formed 1week before and at 6 and 12 months after transplantation. The
insulin secretion and sensitivity index were calculated by OGTT.
Measurement of carotid IMT
Ultrasonography of the common carotid artery (CCA) was conducted bi-
laterally by high-resolution B-mode ultrasonography (LOGIQ9, GE Med-
ical Systems, Milwaukee, WI) with a 10-MHz linear transducer by a
single sonographer who was unaware of the subject's characteristics, as
previously described [14]. A sonographer scanned the left and right
CCAs, the carotid bulb and the proximal portion of the internal and ex-
ternal carotid arteries in three planes (anterior oblique, lateral and poste-
rior oblique views) and then focused on the interfaces required to measure
IMT. Computer-assisted acquisition, processing, storage of B-mode
images and calculation of IMT were performed with Intima Scope soft-
ware (MediaCross, Tokyo, Japan) as previously described [14,15]. The
IMTwas measured by using an automated edge-detection algorithm based
on significant changes in the density of a section between the lumen and
subadventitial structures perpendicular to the vessel wall. The software
estimated the length of lines at the lumen–intima interface and the me-
dia–adventitia interface on the basis of 30-point pixels per 3mm obtained
from tertiary multiple regression analysis incorporating the least squares
method, which was designed to achieve increased accuracy and reproduc-
ibility with reduced variability for the measurements of IMT. Two mea-
surements on longitudinal views of both the right and left common carotid
arteries were made at the segment 20mm distal to the carotid bulbs. For
each measurement, the average and maximum values were calculated au-
tomatically. The average value of IMT was obtained by a computerized
calculation from the area detected.
Reading and analysis of the images were conducted at the end of the
study by a well-trained physician who was blinded to the identity of the
patient, time point and treatment. The intraobserver coefficient of vari-
ance was 2.1%.
Measurement of metabolic parameters
Trough cyclosporine (CsA), tacrolimus level, plasma glucose, blood urea
nitrogen, creatinine, aspartate aminotransferase (AST) [16] and alanine
aminotransferase (ALT) levels were measured at each visit. HbA1c, free
fatty acids, lipid profiles, plasma adiponectin, resistin concentration and
high-sensitivity C-reactive protein (hsCRP) levels were measured before
and 12 months after transplantation.
All samples were obtained in the morning after an overnight fast. Low-
density lipoprotein (LDL) cholesterol was calculated according to Friede-
wald's formula. The hsCRP level was measured as previously described
[17]. HbA1C values were determined by high-performance liquid chro-
matography (Variant II; Greencross, Seoul, Korea). Insulin concentrations
were measured using a radioimmunoassay kit (IRMA kit; DAINABOT,
Tokyo, Japan). Plasma adiponectin and resistin concentrations were mea-
sured using a commercial multiplexed immunoassay kit (Linco Research,
Inc., St. Louis, MO, USA).
OGTT-derived insulin secretion and sensitivity index
For assays of plasma glucose and insulin, blood samples were taken at 0,
30, 60, 90 and 120min after the ingestion of 75g glucose. The secretion
area under the curve (SecrAUC), the first and second phase insulin secre-
tion (Secr1PH, Secr2PH) and the insulin sensitivity index for transplan-
tation (ISITX) were estimated as previously described [18,19].
SecrAUC = AUCIns/AUCGluc, Secr1PH = 1283+(1.829 × Ins30 min)−
(138.7 × Gluc30 min)+(3.772 × Ins0 min), Secr2PH = 287+(0.4164 ×
Ins30 min)−(26.07 × Gluc30 min)+(9.226 × Ins0 min) and ISITX = 0.208−
0.0032 × BMI (kg/m2)−0.0000645 × Ins120 min (pmol/l)−0.00375 ×
Gluc120 min (mmol/l).
PTDM, impaired fasting glucose (IFG) and impaired glucose tolerance
(IGT) were diagnosed according to the American Diabetes Association
criteria [20].
Immunosuppression schedule
The main immunosuppressive regimens consisted of calcineurin inhibi-
tors (CsA or tacrolimus) and glucocorticoids. A regimen of calcineurin
inhibitors was begun 2days before the transplantation. Initially, the doses
of CsA (10mg/kg) and tacrolimus (0.3mg/kg) were administered twice
daily. The target trough levels of CsA and tacrolimus were as follows:
(1) Months 0–3: 150–300ng/ml for CsA and 10–20ng/ml for tacrolimus;
(2) Months 3–6: 150–200ng/ml for CsA and 10–15ng/ml for tacrolimus;
and (3) 6months: 75–150ng/ml for CsA and 8–10ng/ml for tacrolimus.
Administration of oral prednisolone at 1mg/kg/day began 2days before
the transplantation. Methylprednisolone was administered intravenously
for the first four postoperative days in a tapered fashion: Day0, 1g;
Day1, 500mg; Day2, 250mg; and Day3, 60mg. Administration of oral
prednisolone began after the fourth post-transplantation day at 30mg/day
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and was gradually tapered to 10mg/day within 1month. For acute rejec-
tion, a total of 2g methylprednisolone was administered for 5days. For
patients on the triple regimen, the target plasma trough levels of CsA
and tacrolimus were lower than for those on the double regimen: 75–
100ng/ml for CsA and 5–10ng/ml for tacrolimus.
Statistical analyses
We calculated the necessary sample size based on a study of the effects of
pioglitazone on carotid IMT in type 2 diabetes patients and a study of
changes in carotid IMT during the early post-transplant period [11,21].
Calculations of sample size were based on the change of carotid IMT in
both groups (control group = 0.022 ± 0.0437mm vs pioglitazone group =
−0.084 ± 0.1674mm). It was predicted that a final sample size of 48 par-
ticipants would be required for 90% power at P = 0.05. In anticipation of a
20% dropout rate, we intended to recruit at least 60 participants.
All continuous variables were expressed as mean ± standard deviation
(SD). For continuous data, the independent t-test was used. The χ2 test
was implemented for categorical data as appropriate. An independent t-
test was used to analyse the differences between the pioglitazone and con-
trol groups with regard to changes from baseline to end-point measure-
ments, and changes within the groups were analysed by paired t-tests.
The relationships between IMT and variables likely to have an influ-
ence were assessed by univariate regression analysis, followed by multi-
variate regression analysis to evaluate the independent association of each
with IMT. Stepwise multivariate analyses were performed with baseline
IMT values and each variable with a P-value <0.20 according to the uni-
variate analysis.
All statistical tests of significance were two-tailed, and P-value <0.05
was considered significant. All analyses were performed using SPSS for
Windows (version 12; SPSS, Chicago, IL).
Fig. 1. Flow diagram of the study.
Table 1. Clinical baseline characteristics
Control
(n = 38)
Pioglitazone
(n = 30) P-value
Age (years) 40.4 ± 10.0 38.3 ± 11.1 0.437
Sex (M/F) 22/16 19/11 0.803
Family history of diabetesa 1 (2.6%) 1 (3.3%) 1.000
Duration of dialysis
(months)
35.8 ± 52.3 22.4 ± 29.3 0.257
HCV infection 0 0
Living unrelated donor 14 (36.8%) 9 (30.0%) 0.613
IFG or IGT 14 (36.8%) 13 (43.3%) 0.625
Calcineurin inhibitor 0.388
CsA 31 (81.6%) 21 (70.0%)
Tacrolimus 7 (18.4%) 9 (30.0%)
Hypertension 36 (94.7%) 26 (86.7%) 0.394
CCB 25 (65.8%) 20 (66.7%) 1.00
ARB or ACEi 10 (26.3%) 6 (20.0%) 0.579
BB 12 (31.6%) 13 (43.3%) 0.448
Antiplatelet therapy 1 (2.6%) 2 (6.7%) 0.579
Statin use 15 (39.5%) 13 (43.3%) 0.807
Acute rejection 1 (2.6%) 2 (6.7%) 0.579
M, male; F, female; HCV, hepatitis C virus; IFG, impaired fasting glu-
cose; IGT, impaired glucose tolerance; CsA, cyclosporine; CCB, calcium
channel blocker; ARB, angiotensin receptor blocker; ACEi, angiotensin-
converting enzyme inhibitor; BB, beta blocker. aFamily history of diabetes
in a first-degree relative.
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Results
Subjects and safety
The disposition of patients in the trial is shown in Figure
1. Four subjects who were assigned to the pioglitazone
group withdrew consent before receiving the drug. Five
subjects in the control group refused to undergo a fol-
low-up OGTT at 6months after transplantation. In the pio-
glitazone group, four subjects withdrew from the study for
personal reasons, three within 1week and one 4weeks after
the start of the study. One withdrew after 5weeks of treat-
ment because of mild lower-extremity oedema; another
subject withdrew after 5months of treatment because of
Pneumocystis carinii pneumonia. Another two patients in
the pioglitazone group developed mild lower-extremity
oedema but did not discontinue pioglitazone. No other
clinical or laboratory adverse events were associated with
the use of pioglitazone.
The two groups were similar with respect to baseline
clinical characteristics (Table 1). There was no significant
difference in CsA or tacrolimus levels, doses or the cu-
mulative dose of prednisolone over 1year between the
control and pioglitazone groups (Table 2). There was
no significant difference in creatinine, AST and ALT le-
vels between both groups (Table 3). The rate of acute re-
jection during the 12-month period for the control group
and pioglitazone group was 10.5% and 13.3%, respec-
tively (P = 0.724).
Changes in metabolic parameters and adipocytokines
after treatment
In both groups, the levels of fasting plasma glucose,
HbA1c, total cholesterol, high-density lipoprotein (HDL)
cholesterol and LDL cholesterol increased, while the levels
of hsCRP decreased at 1year after transplantation (Table
4). Compared to the control group, the pioglitazone group
had significantly lower increases of triglyceride, free fatty
acid (FFA) and LDL cholesterol levels (Table 4).
Adiponectin levels declined in the control group and in-
creased in the pioglitazone group after transplant (P <
0.001). Levels of resistin were lower in both groups com-
pared with levels before transplantation, but the differ-
ences of resistin were not significant in either group.
Changes in carotid IMT
Subjects in the control group showed higher maximum ca-
rotid IMT but no significant changes in mean carotid IMT
during the 12-month study period (Table 4). The mean and
maximum carotid IMT of the pioglitazone group decreased
0.05 ± 0.04 and 0.08 ± 0.05mm, respectively, from base-
line after 12 months (P < 0.001 for both).
As shown in Table 5, a univariate regression analysis
found that pioglitazone treatment and changes in adiponec-
tin are associated with changes in carotid IMT (P < 0.05).
Multivariate regression analysis showed that pioglitazone
treatment is an independent factor associated with carotid
IMT changes after adjusting for baseline IMT and changes
in adiponectin, ISITX and FFA (Table 6). When we repeat-
ed the multivariate analysis using the same variables ex-
cept for piogl i tazone t rea tment , the change in
adiponectin was the only significant factor associated with
carotid IMT changes.
Table 2. Comparison of the cumulative dose of prednisolone, plasma
tacrolimus, CsA trough level and dose during the study period
Control Pioglitazone P-value
Cumulative steroid dose (g/1year) (n = 38) (n = 30)
6.20 ± 0.65 6.48 ± 1.00 0.170
Plasma tacrolimus trough level
(ng/ml)
(n = 7) (n = 9)
1 month 11.9 ± 5.1 12.0 ± 3.0 0.968
3 months 11.8 ± 3.5 10.8 ± 3.4 0.579
6 months 9.1 ± 2.4 10.4 ± 1.9 0.266
9 months 8.5 ± 2.4 9.4 ± 3.7 0.597
12 months 7.7 ± 0.8 8.1 ± 3.9 0.763
Plasma tacrolimus dose (ng/ml)
1 month 9.1 ± 2.9 11.1 ± 4.0 0.274
3 months 8.6 ± 3.3 8.7 ± 3.2 0.954
6 months 7.3 ± 3.0 7.6 ± 3.2 0.866
9 months 7.0 ± 3.1 7.6 ± 4.2 0.763
12 months 6.4 ± 2.8 6.8 ± 3.8 0.809
Plasma CsA trough level (ng/ml) (n = 31) (n = 21)
1 month 180.2 ± 59.0 198.9 ± 41.2 0.342
3 months 144.9 ± 41.7 158.1 ± 30.9 0.348
6 months 140.9 ± 41.5 159.7 ± 37.1 0.216
9 months 119.3 ± 32.2 140.4 ± 29.0 0.080
12 months 128.1 ± 53.9 129.5 ± 28.2 0.934
Plasma CsA dose (ng/ml)
1 month 253.6 ± 51.8 283.9 ± 69.1 0.201
3 months 232.1 ± 44.3 258.9 ± 73.8 0.257
6 months 226.8 ± 47.5 233.9 ± 63.3 0.738
9 months 221.4 ± 45.8 219.6 ± 50.2 0.922
12 months 203.7 ± 69.0 216.1 ± 53.4 0.601
Data are expressed as mean ± SD. CsA, cyclosporine.
Table 3. Comparison of hepatic function and graft function during the study period
Control (n = 38) Pioglitazone (n = 30)
P b-value (absolute change,
between groups)Initial After 1year Pa-value Initial After 1year Pa-value
AST 16.0 ± 6.2 18.1 ± 3.9 0.060 16.6 ± 7.1 19.4 ± 5.2 0.063 0.559
ALT 16.7 ± 8.9 20.2 ± 8.9 0.063 15.6 ± 8.5 17.4 ± 7.2 0.337 0.450
Creatinine 1.30 ± 0.29 1.35 ± 0.40 0.401 1.41 ± 0.26 1.33 ± 0.36 0.144 0.113
Data are expressed as mean ± SD. AST, aspartate aminotransferase; ALT, alanine aminotransferase. aP-values are for the comparison of variables from
the beginning (2weeks after transplantation) to the end point (1year) in each group. bP-values are for the comparison of the absolute change in each
variable between the pioglitazone and control groups.
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Changes in glucose tolerance, insulin sensitivity and
secretion
The prevalence of PTDM was lower at 12 months after re-
nal transplantation than at 6months, but there was no dif-
ference in the prevalence of PTDM between the two
groups (P = 0.494; Figure 2).
Although there was no significant difference in the
mean total glucose concentration during OGTT (AUCglc)
in either group, pioglitazone lessened the increase of mean
total insulin concentration during OGTT (AUCIns) after
transplantation (Table 4, Figure 3). In the control group,
the estimated first phase insulin secretion (from 1052 ±
437 to 1649 ± 887, P < 0.001), second phase insulin secre-
tion (from 3522 ± 2130 to 6462 ± 4253, P < 0.001) and
SecAUC (from 44 ± 17 to 68 ± 37, P < 0.001) increased sig-
nificantly 1year after transplantation. These secretory func-
tion indices did not change significantly in the pioglitazone
group. Pioglitazone treatment increased the ISITX level in
comparison with that of the control group (pioglitazone
vs control −0.8 ± 3.0×10−2 vs +1.1 ± 3.7×10−2, P = 0.036).
Discussion
The major findings of the present study are that pioglita-
zone treatment may reduce the progression of carotid IMT
Table 4. Changes in clinical and metabolic parameters in the control and pioglitazone groups
Control (n = 38) Pioglitazone (n = 30)
P b-value (absolute change,
between groups)Before After 1year Pa-value Before After 1year Pa-value
Body weight (kg) 58.6 ± 13.5 60.9 ± 10.1 0.175 59.7 ± 10.5 61.2 ± 10.2 0.070 0.600
BMI (kg/m2) 21.4 ± 4.2 22.3 ± 2.8 0.155 21.2 ± 2.4 21.7 ± 2.4 0.057 0.593
Systolic BP (mmHg) 136.6 ± 17.0 125.7 ± 12.0 0.002 134.6 ± 10.9 124.7 ± 12.8 0.001 0.805
Diastolic BP (mmHg) 85.9 ± 9.4 79.3 ± 10.9 0.005 85.2 ± 9.0 74.4 ± 7.8 <0.001 0.141
FPG (mmol/l) 4.61 ± 0.58 5.34 ± 0.75 <0.001 4.61 ± 0.52 5.21 ± 0.96 0.002 0.349
Fasting insulin (pmol/l) 40.9 ± 33.8 82.4 ± 36.8 <0.001 39.2 ± 24.1 58.4 ± 25.1 0.282 0.024
Glucose AUC (mmol/l×2h) 30.8 ± 6.6 30.0 ± 5.2 0.479 31.1 ± 5.5 30.6 ± 8.6 0.786 0.910
Insulin AUC (pmol/l×2h) 1341 ± 541 2050 ± 1319 0.003 1300 ± 729 1268 ± 728 0.842 0.009
HbA1c (%) 4.96 ± 0.50 5.63 ± 0.52 <0.001 4.95 ± 0.56 5.65 ± 0.53 <0.001 0.809
Total cholesterol (mmol/l) 4.11 ± 0.91 5.22 ± 0.85 <0.001 4.08 ± 0.79 5.05 ± 0.73 <0.001 0.527
Triglyceride (mmol/l) 1.89 ± 1.05 2.42 ± 1.91 0.136 2.16 ± 1.22 1.61 ± 0.70 0.012 0.010
HDL cholesterol (mmol/l) 1.04 ± 0.24 1.62 ± 0.36 <0.001 1.15 ± 0.31 1.87 ± 0.46 <0.001 0.186
LDL cholesterol (mmol/l) 2.48 ± 0.74 3.35 ± 0.83 <0.001 2.38 ± 0.56 2.74 ± 0.58 0.014 0.018
FFA (μEq/l) 326 ± 212 540 ± 231 0.001 447 ± 241 440 ± 174 0.875 0.004
hsCRP (mg/l) 3.02 ± 7.22 0.21 ± 0.35 0.043 4.72 ± 9.49 0.48 ± 1.08 0.022 0.520
Adiponectin (μg/ml) 32.35 ± 10.70 20.40 ± 11.74 0.001 24.86 ± 10.48 73.06 ± 35.91 <0.001 <0.001
Resistin (ng/ml) 50.50 ± 25.58 25.83 ± 11.62 <0.001 41.39 ± 39.39 18.10 ± 8.04 0.014 0.884
Mean carotid IMT (mm) 0.54 ± 0.06 0.57 ± 0.10 0.062 0.53 ± 0.09 0.49 ± 0.08 <0.001 <0.001
Maximum carotid IMT (mm) 0.65 ± 0.07 0.70 ± 0.13 0.010 0.67 ± 0.10 0.59 ± 0.09 <0.001 <0.001
Data are expressed as mean ± SD. BP, blood pressure; BMI, body mass index; FPG, fasting plasma glucose; AUC, area under the curve; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; FFA, free fatty acid; IMT, intima–media thickness. aP-values are for the comparison of variables
from baseline (before transplantation) to the end point (1year) in each group. bP-values are for the comparison of the absolute change in each variable
between the pioglitazone and control groups.
Table 5. Univariate regression analyses with the change in carotid IMT as
a dependent variable and clinical parameters as independent variables
Variables
Δ Mean
carotid IMT
Δ Maximum
carotid IMT
β P β P
Age 0.001 0.430 0.001 0.494
Sexa −0.005 0.794 −0.007 0.814
Aspirin useb 0.013 0.787 0.042 0.554
Acute rejectionb 0.031 0.337 0.007 0.877
Pioglitazone treatmentb 0.075 <0.001 0.133 <0.001
Δ Systolic BP <0.001 0.749 −0.001 0.367
Δ Triglyceride 9.065 0.237 9.945 0.369
Δ LDL cholesterol <0.001 0.605 <0.001 0.678
Δ FFA 5.050 0.175 3.945 0.462
Δ hsCRP 0.001 0.460 0.001 0.547
Δ Adiponectin −0.001 0.011 −0.001 0.001
Δ Resistin <0.001 0.500 <0.001 0.383
Δ SecrAUC 8.856 0.776 <0.001 0.670
Δ ISITX −0.453 0.138 −0.577 0.185
Δ indicates change of each parameter between baseline and 12months.
IMT, intima–media thickness; BP, blood pressure; LDL, low-density lipo-
protein; FFA, free fatty acid; SecrAUC, secretion area under the curve;
ISItx, insulin sensitivity index for transplantation.
a0 = male; 1 = female.
b0 = no; 1 = yes.
Table 6. Multiple linear regression analyses with the change in carotid
IMT as a dependent variable and clinical parameters as independent
variables
Variable
Δ Mean
carotid IMT
Δ Maximum
carotid IMT
β P β P
Step 1
Pioglitazone treatmenta 0.091 0.002 0.149 <0.001
Step 2
Δ Adiponectin −0.001 0.016 −0.002 0.001
In Step 1, stepwise multivariate analyses were performed with pioglita-
zone treatment, baseline IMT, Δ adiponectin, Δ ISITX and Δ FFA as in-
dependent variables. In Step 2, stepwise multivariate analyses were
performed with baseline IMT values, Δ adiponectin, Δ ISITX and Δ
FFA as independent variables. Δ indicates change of each parameter be-
tween baseline and 12months. a0 = no; 1 = yes.
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and that it may improve insulin resistance in renal allograft
recipients without a history of diabetes.
It is estimated that CVDs (primarily atherosclerosis and
coronary artery disease) are responsible for 40–55% of all
deaths after kidney transplantation [22]. Carotid IMT has
been established as an early marker of atherosclerosis and
has been associated with the prevalence and incidence of
CVD. Carotid IMT in transplant patients is significantly
greater in the short period after renal transplantation than
in healthy individuals [23]. The rate of carotid IMT in-
crease is high during the first 6 months after transplanta-
tion, even in asymptomatic patients without major
cardiovascular risk factors [21]. Although our observed
baseline carotid IMT was relatively thin compared to
that of previous studies because of the large proportion
of young renal allograft patients in our study, the control
group showed a significant increase in maximum carotid
IMT 1year after transplantation compared with that at
baseline [21,23]. In contrast, patients receiving pioglita-
zone had a thinner carotid IMT at 12months than at
baseline.
Until now, clinical trials with statin drugs and homocys-
teine-lowering therapy have shown a regression of carotid
IMT in renal transplant recipients [16,24]. However, to our
knowledge, no previous studies have examined the effects
of pioglitazone on carotid IMT in renal transplant recipi-
ents. The observed beneficial effect of pioglitazone on ca-
rotid IMT is consistent with the findings of the studies of
type 2 diabetes patients [9,11]. Moreover, Nissen et al. re-
ported recently that treatment with pioglitazone resulted in
a significantly lower rate of coronary atherosclerosis pro-
gression than glimepiride in patients with type 2 diabetes
and coronary artery disease [25].
Pioglitazone increased the adiponectin level, and the
change in adiponectin was negatively correlated with ca-
rotid IMT changes in our study. Pioglitazone treatment
was the only independent parameter associated with
changes in carotid IMT in the multivariate analysis. How-
ever, when the multivariate analysis was repeated using the
same variables except for pioglitazone treatment, which
was omitted to exclude the effects of pioglitazone on the
other variables, the change in adiponectin was an indepen-
dent factor associated with changes in carotid IMT. Based
on these results, we believe that pioglitazone may improve
carotid IMT by increasing adiponectin in renal allograft
recipients. Adiponectin has insulin-sensitizing, anti-ath-
erosclerotic and anti-inflammatory properties. Adiponectin
decreases the expression of adhesion molecules in endo-
thelial cells in response to inflammatory stimuli (including
tumor necrosis factor-α), suppresses cytokine production
in macrophages and inhibits the proliferation of mono-
cytes [26].
It appears that both the pioglitazone group and control
group showed reductions in hsCRP. These results are con-
sistent with those of previous studies [27,28]. End-stage
renal disease (ESRD) per se has been considered pro-in-
flammatory with an ongoing acute phase response. When
renal function improves with a functioning renal transplan-
tation, it is expected that inflammation may be resolved or
improved.
Uraemia is typically associated with impaired glucose
metabolism. Insulin resistance and hyperinsulinaemia have
been demonstrated in patients with chronic renal failure
without clinical diabetes [29]. In contrast, spontaneous hy-
poglycaemia is a complication in both nondiabetic and di-
abetic patients with renal failure. While the evidence
regarding the importance of impaired glucose tolerance
before transplantation is conflicted, a systemic review of
the literature suggests that immunosuppressive drugs ac-
count for 74% of the risk for PTDM development [30].
Nonetheless, when resolving insulin resistance caused by
uraemia after renal transplantation, the use of immunosup-
pressive drugs was an important factor in the development
of PTDM.
We hypothesized that pioglitazone would reduce the in-
cidence of PTDM by improving insulin resistance, which
Fig. 2. Change in the glucose tolerance category from baseline to 12months after renal transplantation. NGT, normal glucose tolerance; IFG, impaired
fasting glucose; IGT, impaired glucose tolerance, PTDM, post-transplant diabetes mellitus.
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contributes to the development of glucose intolerance fol-
lowing renal transplantation. Pioglitazone enhanced insu-
lin sensitivity, thus reducing the demand for insulin
secretion in renal allograft patients. Our results are consis-
tent with the theory that a class effect of thiazolidinediones
reduces the glucose-stimulated insulin secretion rate and
increases insulin clearance in nondiabetic, insulin-resistant
individuals by enhancing insulin sensitivity [31]. Voyto-
vich et al. showed that 4 weeks of rosiglitazone treatment
increased insulin sensitivity but did not change the Se-
crAUC and estimated first and second phase insulin secre-
tion rates in renal allograft recipients with glucose
intolerance [8]. These results are similar to those obtained
in our study; however, the fasting glucose and glucose
AUC were significantly reduced after rosiglitazone treat-
ment. It is possible that the subjects of this study com-
prised seven recipients with PTDM and three with IGT.
We were unable to find any protective effects of piogli-
tazone on the development of PTDM in our study. Based
on previous studies, impaired insulin secretion is the im-
portant factor in the development of PTDM [32–34].
Our control group showed significantly increased insulin
secretion indices (SecrAUC, Secr1PH and Secr2PH) at 1
year after transplantation, indicating that our control group
compensated relatively well for insulin action defects and
remained normoglycaemic until 1year after transplanta-
tion. Thus, the incidence of PTDM in the control group
may be low and we cannot find the difference of the inci-
dence of PTDM in both groups. We believe that, after
long-term follow-up, the control group may have an in-
creased incidence of PTDM compared with the pioglita-
zone group. Therefore, we cannot exclude the possibility
that the absence of a protective effect of pioglitazone on
the development of PTDM is due to the recent low inci-
dence of PTDM, the small number of subjects and the
short follow-up duration in this study.
Pioglitazone, which does not induce CYP3A4, is known
to have no significant impact on kidney function and tacro-
limus levels or doses in renal transplant recipients [7,35].
Moreover, recent studies have shown that thiazolidine-
dione administration was associated with some benefits
in an animal model of chronic CsA nephrotoxicity
[36,37]. We found that pioglitazone did not have any rele-
vant effect on CsA or tacrolimus levels or doses. Renal and
hepatic function also remained unchanged during pioglita-
zone treatment. Three subjects in the pioglitazone group
developed mild lower-extremity oedema.
Our study has some limitations. First, our study popula-
tion had normal carotid IMT at baseline, and the change in
carotid IMT after pioglitazone treatment was relatively
small. Second, pioglitazone may have a direct effect on ar-
terial tension, so carotid IMT may be affected by wall ten-
sion. Measuring the carotid intima–media area may be
helpful to rule out this effect. Third, dialysis and ESRD
can alter glucose metabolism, so it may cause errors to in-
clude or exclude diabetic patients during enrollment [38].
Fourth, the glucose-lowering effect of pioglitazone was not
definitively found in renal allograft recipients. Finally, the
sample size was small and the follow-up period was rela-
tively short. Despite such limitations, we believe that our
results are valuable in showing the protective effect of pio-
glitazone on cardiovascular risk in nondiabetic renal allo-
graft recipients.
In conclusion, pioglitazone treatment decreased the
progression of subclinical atherosclerosis and insulin resis-
tance in nondiabetic renal allograft recipients. The benefi-
cial effects of pioglitazone may help to diminish the risk of
post-transplant CVD. Larger controlled trials of longer
duration are warranted to assess the preventive effect of
pioglitazone on atherosclerosis, glucose intolerance and
safety.
Conflict of interest statement. None declared. The results presented in
this paper have not been published previously in whole or part, except
in abstract form.
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